Omnicell, Inc. (NASDAQ:OMCL) Receives $58.50 Average PT from Brokerages

Shares of Omnicell, Inc. (NASDAQ:OMCL) have earned an average rating of “Moderate Buy” from the eight ratings firms that are presently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, one has given a hold rating and six have assigned a buy rating to the company. The average 1-year target price among analysts that have covered the stock in the last year is $58.50.

Several analysts have recently weighed in on the stock. KeyCorp upgraded shares of Omnicell from a “sector weight” rating to an “overweight” rating and set a $60.00 price objective for the company in a research note on Wednesday, January 7th. Wall Street Zen cut shares of Omnicell from a “buy” rating to a “hold” rating in a report on Saturday, February 7th. Zacks Research raised shares of Omnicell from a “strong sell” rating to a “hold” rating in a research note on Tuesday, March 10th. UBS Group set a $60.00 price objective on shares of Omnicell and gave the company a “buy” rating in a report on Friday, March 13th. Finally, Bank of America raised shares of Omnicell from a “neutral” rating to a “buy” rating and set a $70.00 price objective on the stock in a research report on Wednesday, February 4th.

Insiders Place Their Bets

In other Omnicell news, EVP Corey J. Manley sold 7,405 shares of the stock in a transaction that occurred on Monday, March 16th. The stock was sold at an average price of $34.69, for a total value of $256,879.45. Following the transaction, the executive vice president owned 96,717 shares in the company, valued at approximately $3,355,112.73. This represents a 7.11% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 2.52% of the company’s stock.

Hedge Funds Weigh In On Omnicell

A number of large investors have recently modified their holdings of the company. Raymond James Financial Inc. bought a new position in shares of Omnicell during the 2nd quarter worth approximately $26,000. First Horizon Corp purchased a new position in shares of Omnicell in the 3rd quarter worth approximately $31,000. Farther Finance Advisors LLC grew its holdings in shares of Omnicell by 784.8% in the third quarter. Farther Finance Advisors LLC now owns 1,168 shares of the company’s stock valued at $36,000 after acquiring an additional 1,036 shares in the last quarter. Clearstead Advisors LLC increased its position in shares of Omnicell by 12,180.0% during the fourth quarter. Clearstead Advisors LLC now owns 1,228 shares of the company’s stock valued at $56,000 after acquiring an additional 1,218 shares during the last quarter. Finally, Kemnay Advisory Services Inc. purchased a new stake in shares of Omnicell during the fourth quarter valued at approximately $58,000. 97.70% of the stock is currently owned by institutional investors.

Omnicell Stock Up 0.7%

Shares of NASDAQ:OMCL opened at $35.20 on Tuesday. Omnicell has a 1 year low of $22.66 and a 1 year high of $55.00. The company has a debt-to-equity ratio of 0.14, a current ratio of 1.43 and a quick ratio of 1.22. The business’s 50-day moving average is $41.00 and its 200-day moving average is $38.53. The company has a market capitalization of $1.60 billion, a price-to-earnings ratio of 880.22, a P/E/G ratio of 1.25 and a beta of 0.79.

Omnicell (NASDAQ:OMCL) last released its earnings results on Thursday, February 5th. The company reported $0.40 EPS for the quarter, missing the consensus estimate of $0.47 by ($0.07). The business had revenue of $313.98 million for the quarter, compared to analyst estimates of $313.36 million. Omnicell had a return on equity of 3.00% and a net margin of 0.17%.The company’s revenue for the quarter was up 2.3% on a year-over-year basis. During the same period in the prior year, the business earned $0.60 EPS. Omnicell has set its Q1 2026 guidance at 0.260-0.360 EPS and its FY 2026 guidance at 1.650-1.850 EPS. Equities research analysts predict that Omnicell will post 1.09 earnings per share for the current year.

Omnicell Company Profile

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.